Similar articles for PMID: 24337604

Year	Number of Results
2004	11
2006	2
2007	3
2008	3
2009	8
2010	7
2011	7
2012	15
2013	19
2014	23
2015	13
2016	21
2017	16
2018	12
2019	12
2020	22
2021	37
2022	42
2023	14
2024	0

1

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA. Mortimer JE, et al. J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630. Epub 2013 Dec 12. J Nucl Med. 2014. PMID: 24337604 Free PMC article.

2

Tumor Uptake of ⁶⁴Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.

Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, Poku EK, Rockne RC, Raubitschek AA, Shively JE, Colcher DM. Mortimer JE, et al. J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21. J Nucl Med. 2018. PMID: 28637802 Free PMC article.

3

64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y. Tamura K, et al. J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12. J Nucl Med. 2013. PMID: 24029656 Free article.

4

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S. Gebhart G, et al. J Nucl Med. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271. Epub 2013 Oct 3. J Nucl Med. 2013. PMID: 24092940 Free article. Clinical Trial.

5

Use of ⁶⁴Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study.

Mortimer JE, Bading JR, Frankel PH, Carroll MI, Yuan Y, Park JM, Tumyan L, Gidwaney N, Poku EK, Shively JE, Colcher DM. Mortimer JE, et al. J Nucl Med. 2022 Aug;63(8):1145-1148. doi: 10.2967/jnumed.121.262940. Epub 2021 Dec 2. J Nucl Med. 2022. PMID: 34857660 Free PMC article.

6

Diagnostic value of ⁶⁸ Ga-DOTATATE PET-CT imaging for staging of ER⁺ /PR⁺ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and ¹⁸ F-FDG PET-CT in a prospective pilot trial.

Nguyen A, Fullard K, Sheehan-Dare G, Tang R, Chan L, Ho B, Dear R, Keane J, Hickey A, Nandurkar R, Chen J, Chen A, Lim E, Emmett L. Nguyen A, et al. J Med Imaging Radiat Oncol. 2022 Sep;66(6):731-737. doi: 10.1111/1754-9485.13342. Epub 2021 Oct 21. J Med Imaging Radiat Oncol. 2022. PMID: 34676675

7

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.

Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Watanabe S, Ishioka NS, Endo K. Paudyal P, et al. Cancer Sci. 2010 Apr;101(4):1045-50. doi: 10.1111/j.1349-7006.2010.01480.x. Epub 2009 Dec 22. Cancer Sci. 2010. PMID: 20219072 Free article.

8

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Gebhart G, et al. Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598545 Free article. Clinical Trial.

9

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. Ulaner GA, et al. Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820. Clin Nucl Med. 2017. PMID: 28872549 Free PMC article. Clinical Trial.

10

First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. Ulaner GA, et al. J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16. J Nucl Med. 2018. PMID: 29146695 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

228 results

Results by year